Kronos Bio Announces First Patient Dosed with KB-0742 in an Expansion Cohort Focused on Platinum-Resistant High-Grade Serous Ovarian Cancer

Core Insights - Kronos Bio, Inc. is advancing its clinical-stage drug KB-0742, targeting platinum-resistant high-grade serous ovarian cancer (HGSOC) with promising early results [1][4][11] - The company plans to provide an efficacy update on KB-0742 in the first half of 2025, highlighting its potential to offer new treatment options for patients with limited alternatives [1][9] Company Overview - Kronos Bio, Inc. focuses on developing small molecule therapeutics that target deregulated transcription, a common feature in cancer and other diseases [1][4] - The company utilizes a proprietary discovery engine to identify druggable cofactors within complex transcription factor regulatory networks [1] Product Details - KB-0742 is a selective oral inhibitor of CDK9, which is crucial for the activity of the oncogenic MYC transcription factor [11] - The drug is currently in a Phase 1/2 open-label study, specifically targeting MYC-amplified and transcriptionally addicted solid tumors [11] Clinical Trial Information - The first patient in the expansion cohort has been dosed with KB-0742 at an 80mg dose on a four-days-on, three-days-off schedule [4] - The drug has shown preliminary anti-tumor activity in transcriptionally addicted solid tumors at a lower dose of 60mg [9] Market Context - In the U.S., there are approximately 22,000 new cases of ovarian cancer annually, with a five-year survival rate of less than 50% [5] - About 85% of these tumors exhibit MYC amplification or overexpression, and 50% are classified as HRD+ [5]